Last reviewed · How we verify
Transcutaneous mode of administration — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Transcutaneous mode of administration (Transcutaneous mode of administration) — Objectif Recherche Vaccins SIDA.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Transcutaneous mode of administration TARGET | Transcutaneous mode of administration | Objectif Recherche Vaccins SIDA | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Transcutaneous mode of administration CI watch — RSS
- Transcutaneous mode of administration CI watch — Atom
- Transcutaneous mode of administration CI watch — JSON
- Transcutaneous mode of administration alone — RSS
Cite this brief
Drug Landscape (2026). Transcutaneous mode of administration — Competitive Intelligence Brief. https://druglandscape.com/ci/transcutaneous-mode-of-administration. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab